Statin Therapy and Portal Pressure Reduction in Cirrhosis: A Systematic Review and Meta‐Analysis
Liver International · 2025
DOI: 10.1111/liv.70326 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Liver International, 2025. Verfasst von Eyad Abdulrazzak und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypertension, Portal, Liver Cirrhosis, Portal Pressure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
Background and Aims Portal hypertension is the principal driver of cirrhosis decompensation, leading to heightened morbidity and mortality. While non‐selective beta‐blockers (NSBBs) remain the standard of care, up to 45% of patients fail to achieve sufficient portal pressure reduction. Statins have gained attention as a potential therapeutic agent for portal hypertension. We conducted a systematic review and meta‐analysis of randomised controlled trials (RCTs) to evaluate the impact of statins on portal pressure and cirrhosis‐related outcomes.
Methods
We searched five databases through November 2024 for RCTs evaluating statin therapy in adults with cirrhosis and clinically significant portal hypertension (CSPH). The primary outcome was HVPG reduction, assessed as an absolute decrease or the proportion achieving a haemodynamic response (HVPG reduction ≥ 20% from baseline or to ≤ 12 mmHg). Secondary outcomes included variceal bleeding, ascites and mortality. Random‐effects meta‐analyses were performed using pooled mean differences (MDs) and risk differences (RDs) with 95% confidence intervals (CIs).
Results
Six RCTs ( n = 492) were included. Statin therapy was associated with significant HVPG reduction (MD: 1.1 mmHg; 95% CI: 0.44–1.77; I 2 = 38.7%) and higher hemodynamic response (RD: 0.24; 95% CI: 0.02–0.45; I 2 = 76.8%). No significant differences were seen in variceal bleeding, ascites or mortality. On subgroup analysis, HVPG benefit was limited to studies with short‐term follow‐up. In studies comparing statin plus NSBB to NSBB alone, the addition of statins further reduced HVPG.
Conclusions
Statins modestly lower HVPG in cirrhosis‐related portal hypertension and may be a useful adjunct to NSBBs. Larger trials are needed to assess long‐term clinical benefits. Trial Registration PROSPERO registration number: CRD42025622478
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Medicine, Virginia Commonwealth University Health, Richmond, Virginia, USA.
- Department of Medicine, Rochester General Hospital, Rochester, New York, USA.
- Department of Medicine, Ascension St. Joseph Hospital, Chicago, Illinois, USA.
- Department of Medicine, Tower Health-Phoenixville Hospital, Phoenixville, Pennsylvania, USA.
- Division of Gastroenterology, UHS Wilson Medical Center, Johnson City, New York, USA.
ORCID-Profile: Eyad Abdulrazzak, Butros Fakhoury, Leandro Sierra, Hazem Abosheaishaa
Zitieren
APA
Abdulrazzak, E., Fakhoury, B., Jaan, A., Ebrahim, M., Alabdul Razzak, I., Shehadah, A., Sierra, L., Abosheaishaa, H., Tapper, E. B., & Trivedi, H. D. (2025). Statin Therapy and Portal Pressure Reduction in Cirrhosis: A Systematic Review and Meta‐Analysis. Liver International. https://doi.org/10.1111/liv.70326
Vancouver
Abdulrazzak E, Fakhoury B, Jaan A, Ebrahim M, Alabdul Razzak I, Shehadah A, et al. Statin Therapy and Portal Pressure Reduction in Cirrhosis: A Systematic Review and Meta‐Analysis. Liver International. 2025. doi:10.1111/liv.70326
BibTeX
@article{Abdulrazzak2025,
author = {Abdulrazzak, Eyad and Fakhoury, Butros and Jaan, Ali and Ebrahim, Mohamed and Alabdul Razzak, Imad and Shehadah, Ahmed and Sierra, Leandro and Abosheaishaa, Hazem and Tapper, Elliot B and Trivedi, Hirsh D},
title = {Statin Therapy and Portal Pressure Reduction in Cirrhosis: A Systematic Review and Meta‐Analysis},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70326}
}
EUVIMED